Next Article in Journal
Phytogalactolipid dLGG Inhibits Mouse Melanoma Brain Metastasis through Regulating Oxylipin Activity and Re-Programming Macrophage Polarity in the Tumor Microenvironment
Next Article in Special Issue
Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy
Previous Article in Journal
Genomic Mapping of Splicing-Related Genes Identify Amplifications in LSM1, CLNS1A, and ILF2 in Luminal Breast Cancer
Previous Article in Special Issue
Prognostic Value of the Hemoglobin/Red Cell Distribution Width Ratio in Resected Lung Adenocarcinoma
Review

Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future

1
The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 84105, Israel
2
Medical School for International Health, Ben-Gurion University of the Negev, Beer Sheva 84101, Israel
3
Bnai Zion Medical Centre, Oncology Division and Cancer Institute, Haifa 31048, Israel
*
Author to whom correspondence should be addressed.
Academic Editor: Francesco Petrella
Cancers 2021, 13(16), 4119; https://doi.org/10.3390/cancers13164119
Received: 13 July 2021 / Revised: 12 August 2021 / Accepted: 13 August 2021 / Published: 16 August 2021
(This article belongs to the Special Issue Diagnosis and Treatment of Primary and Secondary Lung Cancers)
This review article details the progress of lung cancer treatments for a subtype known as non-small cell lung cancer with a special mutation of epidermal growth factor receptor (EGFR). In the following review article, we included the past trials that exclusively involved the chemotherapy treatments, present trials that explore the use of drugs known as tyrosine kinase inhibitors (different generations of EGFR- TKIs), as well as the ongoing trials that consider an interplay between these two. Finally, we propose some areas of future research given the implications of the current studies, namely regarding metastasis to the brain and central nervous system.
Lung cancer is the most common malignancy across the world. The new era in lung cancer treatments, especially this past decade, has yielded novel categories of targeted therapy for specific mutations and adjuvant therapy, both of which have led to improved survival rates. In the present study, we review the changes and development of treatments, with a special focus on adjuvant therapy using tyrosine kinase inhibitors (TKIs) administered to non-small-cell lung carcinoma patients who had a complete resection of the tumor harboring a mutated epidermal growth factor receptor. The clinical trials are dating from the past (chemotherapy trials), present (TKIs), and future (ongoing trials). View Full-Text
Keywords: lung cancer; adjuvant treatment; non-small-cell lung carcinoma (NSCLC); epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI) lung cancer; adjuvant treatment; non-small-cell lung carcinoma (NSCLC); epidermal growth factor receptor (EGFR); tyrosine kinase inhibitor (TKI)
MDPI and ACS Style

Shalata, W.; Jacob, B.M.; Agbarya, A. Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future. Cancers 2021, 13, 4119. https://doi.org/10.3390/cancers13164119

AMA Style

Shalata W, Jacob BM, Agbarya A. Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future. Cancers. 2021; 13(16):4119. https://doi.org/10.3390/cancers13164119

Chicago/Turabian Style

Shalata, Walid, Binil M. Jacob, and Abed Agbarya. 2021. "Adjuvant Treatment with Tyrosine Kinase Inhibitors in Epidermal Growth Factor Receptor Mutated Non-Small-Cell Lung Carcinoma Patients, Past, Present and Future" Cancers 13, no. 16: 4119. https://doi.org/10.3390/cancers13164119

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop